(RTTNews) - Intellia Therapeutics, Inc. (NTLA) reported positive interim results from an ongoing phase 1/2 clinical study of NTLA-2002, the company's second in vivo genome editing candidate being developed for hereditary angioedema. In the study, a single dose of NTLA-2002 led to a 65% and 92% mean plasma kallikrein reduction at 25 mg and 75 mg doses, respectively, at week eight. Hereditary angioedema attacks were reduced by 91% in the 25 mg dose cohort through week 16. At both dose levels, NTLA-2002 was generally well-tolerated, the company noted.
The company plans to initiate the phase 2 dose-expansion portion of the study in the first half of 2023.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
